Contents
Issue 119 • June 2022
In association with
In association with
Comment
CMO agreements need to go public, but ‘glib’ onshoring not the answer
Biologic sales forecast to pass innovative small molecule sales in next five years
The telemedicine community has rallied to provide support to patients in Ukraine
Osteoarthritis pipeline shifting from analgesics to disease-modifying treatments
In Depth
Continuous manufacturing builds on hype but adoption remains gradual
Can Relmada’s fast-acting pill for major depressive disorder compete in a crowded market?
Access to CAR-T therapies in Central and Eastern Europe in “catch-up” mode compared to the West
How ambitious are the emissions targets of pharma and biotech companies?
Should Covid-19 clinical trial plans still centre around EUAs?
Comment
The telemedicine community has rallied to provide support to patients in Ukraine